Patients with HCV genotype @ or @ infection ( n = @ ) , enrolled at research centers in North America , Europe , or Australia , were assigned randomly to groups given @ or @ weeks of daclatasvir ( @ mg once daily ) , or @ weeks of placebo , each combined with peginterferon alfa-@a and ribavirin .